

Bevacizumab ICON7

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

PFS



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Bevacizumab ICON7

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival

1



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

Experimental Arm: Bevacizumab + Paclitaxel + carboplatin

Control Arm: Paclitaxel + carboplatin



